Streetbeat News

Revenues

ENPH

Enphase Energy has expanded its distribution partnership with AC Solar Warehouse in Australia, aiming to increase the availability of Enphase products in the Australian market. This move is expected to strengthen Enphase's presence in the region and potentially boost sales.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 1:03 pm

ISPC

iSpecimen has expanded its supplier network and offerings, enhancing access to vital biospecimens for oncology research. This includes new suppliers, strengthened ties with current suppliers, and new product introductions.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 12:33 pm

AZN

BMY

The Biden administration is considering using 'march-in rights' to seize patents for high-cost medications developed with federal funding. A new framework by the Commerce Department will outline criteria for such actions, focusing on drug pricing and public accessibility. Pharmaceutical companies oppose this, claiming it's illegal and could hinder new drug development. AstraZeneca, Bristol Myers Squibb, and Boehringer Ingelheim, despite lawsuits against the administration's drug pricing policies, are open to Medicare price negotiations.

Portfolio Pulse from Vandana Singh

December 07, 2023 | 12:33 pm

SNY

Sanofi SA (NASDAQ:SNY) has announced ambitious plans to bolster its drug pipeline, highlighting 12 potential blockbuster drugs with peak sales ranging from €2 billion to over €5 billion each. CEO Paul Hudson is addressing investor concerns regarding the expanded R&D budget. Sanofi expects its new and existing pharmaceutical assets to generate over €10 billion in annual sales by 2030, with Dupixent expected to see low double-digit growth up to 2030. The company anticipates a 50% increase in Phase 3 studies between 2023-2025, 25 mid- to late-stage read-outs, and up to 19 regulatory submissions in the next two years. The Phase 3 IMROZ trial of Sarclisa showed a significant improvement in progression-free survival for patients with multiple myeloma.

Portfolio Pulse from Vandana Singh

December 07, 2023 | 12:30 pm

DOYU

DouYu International Holdings Limited (NASDAQ: DOYU) reported a Q3 FY23 revenue decline of 24.4% year-on-year to $186.3 million, slightly above consensus estimates. Adjusted earnings per ADS matched consensus at $0.03. Livestreaming revenues fell by 32.5%, while advertising and other revenues surged by 123.2%. The company's gross margin remained stable at 14.2%, with cash reserves of $978.5 million. However, mobile MAUs and paying user count both decreased. Despite the revenue dip, DOYU's stock rose by 1.55% to $0.72.

Portfolio Pulse from Anusuya Lahiri

December 07, 2023 | 12:28 pm

CLMB

Climb Global Solutions' subsidiary, Climb Channel Solutions, announced the expansion of their GSA IT-70 contract to include GFI Software products. This expansion allows Climb Channel Solutions to offer GFI's security and communications software to government agencies, potentially increasing the subsidiary's revenue and market presence in the government sector.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 12:23 pm

KYMR

SNY

Kymera Therapeutics has initiated a Phase 2 clinical trial for KT-474, aimed at treating atopic dermatitis. The first patient dosing has triggered a $15M milestone payment from their collaborator, Sanofi.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 12:09 pm

SCWX

SecureWorks reported its Q4 revenue forecast to be between $86M-$88M, aligning with the $86.88M estimate. The company also anticipates a non-GAAP net loss per share of $(0.03)-$(0.05), which is in line with the $(0.03) estimate.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 12:09 pm

JBLU

JetBlue has updated its Q4 revenue decline forecast to (7.0%)-(4.0%) from the previous (10.5%)-(6.5%). Additionally, the company has revised its FY23 revenue growth projection to 4.0%-5.0%, an improvement from the prior estimate of 3.0%-5.0%.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 12:07 pm

SCWX

SecureWorks reported Q3 sales of $89.36M, slightly beating the consensus estimate of $88.98M. However, this represents a 19.45% decrease from the same period last year. The company ended the quarter with $58.1M in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 12:04 pm